Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study

#1932

Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.

Aim(s): To explore CHOI vs RECIST criteria.

Materials and methods: CRIPNET-GETNE study include patients with advanced unresectable PNET treated with sunitinib who were evaluated by Computed Tomography (CT) using CHOI and RECIST criteria, every 3 months until progression (PD). Choi criteria sets partial response (PR) as a decrease in size of ≥10% or a decrease in tumour density (Hounfield Units, HU) ≥15% on CT. RECIST criteria sets PR as a decrease in size of ≥30% of the sum of diameters.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Solis-Hernandez M, Carmona-Bayonas A, Calvo-Temprano D, Nuñez B, Custodio A,

Keywords: sunitinib, PNET, choi, recist,